Vascular effects of natriuretic peptides in healthy men.

What Was Tested

Researchers studied Atrial Natriuretic Factor in this randomized controlled trial publication.

Furthermore, vascular responses to short and prolonged infusions were compared to investigate rapid hyporesponsiveness of guanylyl-cyclase type A receptor.

Why It Was Studied

Most effects of atrial (ANP) and B-type natriuretic peptide (BNP) result from stimulation of the guanylyl-cyclase type A receptor.

Chronic elevation causes hyporesponsiveness to ANP, whereas BNP effects tend to be preserved, implying an additional pathway of action.

Who Took Part

The study group was 11 volunteers.

The age groups tagged for this paper are adults, men only.

In 6 subjects, infusion time was adjusted to plasma half-lives (5 times), and in the other 5 subjects, infusion time was 5 minutes.

How the Study Was Run

The design is described as randomized.

Because people in this Atrial Natriuretic Factor study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each infusion phase was followed by a washout period.

Then, ANP was restarted, followed by co-infusion of one of the natriuretic peptides not yet infused.

After a further washout period, ANP was restarted, followed by co-infusion of the natriuretic peptide not yet co-infused.

What Was Measured

The subject headings attached to it are Atrial Natriuretic Factor, Guanylate Cyclase, Natriuretic Peptide, Brain, Natriuretic Peptide, C-Type, Receptors, Atrial Natriuretic Factor and Vasodilation.

What This Means in Plain Language

The paper is a randomized study of Atrial Natriuretic Factor in 11 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2004 (Journal of cardiovascular pharmacology and therapeutics), a journal based in United States.

More context: all human trials.